Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials. - Wikidata - wikimedia - TriplyDB

Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials.

Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials.

http://www.wikidata.org/entity/Q44272543

about

Trial Watch Cytokine patterns in cancer patients: A review of the correlation between interleukin 6 and prognosis Homogeneous Biosensing Based on Magnetic Particle Labels Current management and future directions in the treatment of advanced renal cell carcinoma-a latin american perspective: 10 years in review Pazopanib in sarcomas: expanding the PALETTE Molecular marker for predicting treatment response in advanced renal cell carcinoma: does the promise fulfill clinical need?Profile of pazopanib and its potential in the treatment of epithelial ovarian cancer Individualising treatment choices in a crowded treatment algorithm Predictive and prognostic biomarkers of targeted agents and modern immunotherapy in renal cell carcinoma miR-200c Regulation of Metastases in Ovarian Cancer: Potential Role in Epithelial and Mesenchymal Transition Monitoring of the Immune Dysfunction in Cancer Patients Renal cell carcinoma.Analysis of plasma cytokines and angiogenic factors in patients with pretreated urothelial cancer receiving Pazopanib: the role of circulating interleukin-8 to enhance the prognostic accuracy A five-factor biomarker profile obtained week 4-12 of treatment for improved prognostication in metastatic renal cell carcinoma: Results from DARENCA study 2.Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patients Therapeutic potential of TAS-115 via c-MET and PDGFRα signal inhibition for synovial sarcoma.Genetic modulation of the interleukin 6 (IL-6) system in patients with advanced gastric cancer: a background for an alternative target therapy.Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions.High EphA2 protein expression in renal cell carcinoma is associated with a poor disease outcome.Modulation of circulating protein biomarkers following TRC105 (anti-endoglin antibody) treatment in patients with advanced cancer.Phase I study of capecitabine, oxaliplatin, bevacizumab, and everolimus in advanced solid tumors.Adjusting for misclassification in a stratified biomarker clinical trial.Lenvatinib, an angiogenesis inhibitor targeting VEGFR/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage.Investigation of novel circulating proteins, germ line single-nucleotide polymorphisms, and molecular tumor markers as potential efficacy biomarkers of first-line sunitinib therapy for advanced renal cell carcinoma Granulocyte macrophage colony-stimulating factor as a predictor of the response of metastatic renal cell carcinoma to tyrosine kinase inhibitor therapy.Serum protein profiling reveals baseline and pharmacodynamic biomarker signatures associated with clinical outcome in mCRC patients treated with chemotherapy ± cediranib The current status of tailor-made medicine with molecular biomarkers for patients with clear cell renal cell carcinoma.Prognostic and predictive blood-based biomarkers in patients with advanced pancreatic cancer: results from CALGB80303 (Alliance)Biomarkers for anti-angiogenic therapy in cancer.Sites of disease as predictors of outcome in metastatic renal cell carcinoma patients treated with first-line sunitinib or sorafenib.IL8 polymorphisms and overall survival in pazopanib- or sunitinib-treated patients with renal cell carcinoma.Circulating cytokines and monocyte subpopulations as biomarkers of outcome and biological activity in sunitinib-treated patients with advanced neuroendocrine tumours Carbonic anhydrase 9 expression increases with vascular endothelial growth factor-targeted therapy and is predictive of outcome in metastatic clear cell renal cancer.Immunological response and overall survival in a subset of advanced renal cell carcinoma patients from a randomized phase 2/3 study of naptumomab estafenatox plus IFN-α versus IFN-α.CECs and IL-8 Have Prognostic and Predictive Utility in Patients with Recurrent Platinum-Sensitive Ovarian Cancer: Biomarker Correlates from the Randomized Phase-2 Trial of Olaparib and Cediranib Compared with Olaparib in Recurrent Platinum-Sensitiv High expression of interleukin-11 is an independent indicator of poor prognosis in clear-cell renal cell carcinoma Trial Watch: Therapeutic vaccines in metastatic renal cell carcinoma Carbonic anhydrase IX as a potential biomarker of efficacy in metastatic clear-cell renal cell carcinoma patients receiving sorafenib or placebo: analysis from the treatment approaches in renal cancer global evaluation trial (TARGET).Hypertension and Circulating Cytokines and Angiogenic Factors in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma Treated With Sunitinib: Results From a Phase II Trial Association of single nucleotide polymorphisms in IL8 and IL13 with sunitinib-induced toxicity in patients with metastatic renal cell carcinoma.

P2860

Q24618653-7A385F2C-AE31-4C0C-9E0C-D0C5C0DBC384 Q26741263-A0451BA9-33E7-49EC-B579-92259CC71D11 Q26747505-E8005255-E5DC-45F6-BA88-E628DA718E65 Q26774515-50B2F5E3-F8B2-428E-9562-FFC5EF43119C Q26825050-2243AE2B-C911-4E28-8E91-F429D812AD3F Q26825512-43457C12-C8B7-48D9-8E8C-601C8D16A9E8 Q27011840-72E6D912-632A-4F41-986E-2C078EE50C1C Q27023669-3E1E0509-E585-4179-BE0C-74E7FE35D5BB Q28067482-52AC9DE9-8EC7-4D69-8EF8-47699597A17C Q28071987-02F69EFB-A736-4698-B9E4-FC6AC2CF47F2 Q28072712-6D7FB761-6315-4D74-94A9-ABEBFC777249 Q30235364-C6027676-A260-4C2C-9291-E2595896ECA5 Q30563774-BD056FE2-5951-4B95-8E50-4A451CEBA2D6 Q33426559-4B85E18A-61FA-4FFE-972D-42475010602A Q33426958-CE155861-A708-4EEC-ABE9-584A1B39B5D8 Q33696791-1121D07F-F478-4885-91C6-05EDC5BBBE35 Q33714950-F96571EE-72F0-4220-917A-5F6E6D940636 Q33770680-1036F15D-D2DE-4BC3-8228-7129422CB862 Q33844126-AED201B0-6ABE-4673-9F1B-A028B4E3D479 Q33913556-E0F0D0BD-F810-4B56-80CC-FFA55C5508C4 Q33921891-34EDEC5C-9898-4EA4-A980-204ED6CD923F Q33934232-2324F855-AEDF-4719-957A-CCA3D9281543 Q34144848-4D88DC6E-D441-4655-BC60-629A693CC110 Q34243444-05DBA53A-BCC7-4200-831F-614E879FF37B Q34265694-E1C3CB91-D841-4342-AB19-509F7B0D1865 Q34354522-83F92AD4-648A-4A65-96C8-5D2D755D0913 Q34365135-852D73DB-96DF-4D8B-82EC-4EDCF7604D47 Q34447921-61B338FB-69EF-46C9-AE63-677E88DB7FDD Q34695003-BDF95424-3270-4905-A004-2A9886024C1D Q35214229-656A4D41-2DCD-4561-8ACE-7A0C33FF6051 Q35274936-CFF9A26C-D3A5-4CDE-B75A-792495BE55CF Q35274974-B38C8A08-FFDB-4D1C-ACD4-0CE3D6F74C11 Q35540063-52423028-380D-4A3A-AAA7-ED5B8772D0A4 Q35552042-87268245-DA67-4D34-AD3B-4E652F612D1A Q35669792-EAA9E536-0646-4F82-AE7C-A9A3162F8ED0 Q35674197-4F5A6A6B-8965-4F7F-9DE7-45065BC28C24 Q35799377-D3962CE8-B5E3-4ABC-8F3F-BD95ABB0265C Q35909843-6A1703BA-2481-47C1-8FC1-2218308B7BFF Q36116324-558C8045-13F4-4F0D-9268-26E76EDCD9B5 Q36275134-C8750CE9-6298-4B25-AA4A-A4C7D9F6BCC9

P2860

Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials.

http://www.wikidata.org/entity/Q44272543

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh

2012年學術文章

@zh-hant

name

Prognostic or predictive plasm ...... of phase 2 and phase 3 trials.

@en

Prognostic or predictive plasm ...... of phase 2 and phase 3 trials.

@nl

type

label

Prognostic or predictive plasm ...... of phase 2 and phase 3 trials.

@en

Prognostic or predictive plasm ...... of phase 2 and phase 3 trials.

@nl

prefLabel

Prognostic or predictive plasm ...... of phase 2 and phase 3 trials.

@en

Prognostic or predictive plasm ...... of phase 2 and phase 3 trials.

@nl

P1433

Q44272543-F40BBB65-63D5-49F6-B649-3035712115C7

P1476

Q44272543-8FE50CB1-67D2-422D-9BDD-A69D68B34C66

P2093

Q44272543-0B46A082-74F3-4C58-82B0-6B635123EA3F

Q44272543-3D92C9E1-CAFF-4216-A5BA-7F0538E24C74

Q44272543-614D73E7-5E5F-4FC1-B89B-7E7DFA79D662

Q44272543-70D8373A-35CD-4B0D-90AE-5657A618D742

Q44272543-7B295B7C-D7EC-4855-822E-350E92E02D5A

Q44272543-7E9CFCD6-CB9A-4C99-95E8-0DDC318DDD21

Q44272543-95AFA481-D013-4E29-A178-8E37F3D586C0

Q44272543-960F3E9C-FE1C-4029-A501-7F43B1915619

Q44272543-CEFA4945-D21D-4B61-BC4C-DC1C6E67A2F1

Q44272543-DC205226-B064-4588-9857-B951F4F75D82

P304

Q44272543-E36B561D-699A-401A-A43C-4D764C88B99C

P31

Q44272543-F344DBEF-16FF-4D18-9460-0E4015AD09A0

P356

Q44272543-C013147A-2514-45FE-8EA8-BB63B8B4EAE6

P433

Q44272543-BE1BFA22-A30C-4F86-A595-DE75AC98FAB5

P478

Q44272543-B0C496EF-600C-41B4-9C28-B68ECF0AEFF6

P50

Q44272543-6DAC598E-9F75-40EC-AF11-FBD80D24A5D5

P577

Q44272543-BB372C78-1216-4578-9DB9-E5CD39E6BD38

P698

Q44272543-EBD46172-4984-4576-8A4F-96D8C0A2F74C

P921

Q44272543-0A181212-1D54-4798-AFD9-5099A8A1EF9B

Q44272543-1056CA8E-D31F-48D1-B63A-776DD08AF1AB

Q44272543-24C36952-BD87-4C81-B67D-C6DAF8D96D97

Q44272543-5BB15895-7C9D-480D-82FA-2EC492E5D016

P356

S1470-2045(12)70241-3

P1433

The Lancet Oncology

P1476

Prognostic or predictive plasm ...... of phase 2 and phase 3 trials.

@en

P2093

Amado J Zurita

http://www.w3.org/2001/XMLSchema#string

Anne-Marie Martin

http://www.w3.org/2001/XMLSchema#string

Cora N Sternberg

http://www.w3.org/2001/XMLSchema#string

Hai T Tran

http://www.w3.org/2001/XMLSchema#string

Katherine L Baker-Neblett

http://www.w3.org/2001/XMLSchema#string

Lini N Pandite

http://www.w3.org/2001/XMLSchema#string

Rafael G Amado

http://www.w3.org/2001/XMLSchema#string

Robert A Figlin

http://www.w3.org/2001/XMLSchema#string

Thomas E Hutson

http://www.w3.org/2001/XMLSchema#string

Ying Lin

http://www.w3.org/2001/XMLSchema#string

P304

827-837

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/S1470-2045(12)70241-3

http://www.w3.org/2001/XMLSchema#string

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

13

http://www.w3.org/2001/XMLSchema#string

P50

P577

2012-07-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22759480

http://www.w3.org/2001/XMLSchema#string

P921

phase II clinical trial

phase III clinical trial